Affimed N.V. (NASDAQ:AFMD)’s share price dropped 23.1% on Tuesday . The company traded as low as $1.30 and last traded at $1.50. Approximately 2,457,900 shares were traded during trading, an increase of 756% from the average daily volume of 287,207 shares. The stock had previously closed at $1.95.

AFMD has been the topic of a number of research reports. Oppenheimer reissued a “hold” rating on shares of Affimed in a report on Friday, November 24th. ValuEngine cut Affimed from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

The company has a quick ratio of 6.39, a current ratio of 6.43 and a debt-to-equity ratio of 0.14.

Several hedge funds and other institutional investors have recently made changes to their positions in AFMD. Point72 Asset Management L.P. purchased a new position in shares of Affimed during the 3rd quarter valued at about $658,000. Dimensional Fund Advisors LP grew its position in Affimed by 817.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 137,783 shares of the biopharmaceutical company’s stock worth $310,000 after acquiring an additional 122,773 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Affimed during the 2nd quarter worth approximately $144,000. Finally, Nationwide Fund Advisors grew its position in Affimed by 4.6% during the 2nd quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock worth $1,038,000 after acquiring an additional 22,172 shares during the last quarter. 40.50% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at

About Affimed

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with's FREE daily email newsletter.